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Abstract
Background: The conversion of soluble peptides and proteins into polymeric amyloid structures is a hallmark of many age-
related degenerative disorders, including Alzheimer’s disease, type II diabetes and a variety of systemic amyloidoses. We
report here that amyloid formation is linked to another major age-related phenomenon 2 prostate tissue remodelling in
middle-aged and elderly men.
Methodology/Principal Findings: By using multidisciplinary analysis of corpora amylacea inclusions in prostate glands of
patients diagnosed with prostate cancer we have revealed that their major components are the amyloid forms of S100A8
and S100A9 proteins associated with numerous inflammatory conditions and types of cancer. In prostate protease rich
environment the amyloids are stabilized by dystrophic calcification and lateral thickening. We have demonstrated that
material closely resembling CA can be produced from S100A8/A9 in vitro under native and acidic conditions and shows the
characters of amyloids. This process is facilitated by calcium or zinc, both of which are abundant in ex vivo inclusions. These
observations were supported by computational analysis of the S100A8/A9 calcium-dependent aggregation propensity
profiles. We found DNA and proteins from Escherichia coli in CA bodies, suggesting that their formation is likely to be
associated with bacterial infection. CA inclusions were also accompanied by the activation of macrophages and by an
increase in the concentration of S100A8/A9 in the surrounding tissues, indicating inflammatory reactions.
Conclusions/Significance: These findings, taken together, suggest a link between bacterial infection, inflammation and
amyloid deposition of pro-inflammatory proteins S100A8/A9 in the prostate gland, such that a self-perpetuating cycle can
be triggered and may increase the risk of malignancy in the ageing prostate. The results provide strong support for the
prediction that the generic ability of polypeptide chains to convert into amyloids could lead to their involvement in an
increasing number of otherwise apparently unrelated diseases, particularly those associated with ageing.
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Introduction
The reproductive role of the prostate gland decreases with
increasing age, leading to prostate tissue remodelling. This can be
accompanied by serious problems such as benign prostatic
hyperplasia, observed in 70% of men in their 60 s [1], and
prostate cancer [2]. The latter is the most common non-cutaneous
malignant neoplasm in men in Western countries [2]. The
incidence of prostate cancer is rising rapidly with ageing
population and now affects several millions men in Western
world. In USA alone ca. 190 000 new cases are reported yearly
and ca. 29 000 deaths have occurred from prostate cancer in 2008
according to the surveillance of the National Cancer Institute. In
Europe mortality rates from prostate cancer varies significantly
among different countries [3,4]. There is a marked contrast
between Mediterranean regions with below-average mortality and
the other states, where there are several canters of excess mortality,
including Sweden, Denmark, West of Germany, North of France,
Ireland and Netherlands. There is a lack of understanding of the
factors which may affect the increasing incidence of disease and its
obvious geographic pattern. It appears that prostate pathologies
may be a cost of longevity in the post-reproductive period. In
order to provide an insight into the potential causes of prostate
pathologies, we have carried out systematic and multidisciplinary
studies of common prostate inclusions denoted as corpora
amylacea [4], which are found in a significant proportion of
males over the age of 50.
There is a growing body of evidence indicating that inflammation
plays a crucial role in prostate pathogenesis, as it is found to be
associated with 40–90% of benign prostatic hyperplasia [1] as well
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as with 20% of all human cancers [2,5]. CAs are thought to be
linked clinically to asymptomatic prostate inflammation and are
often observed adjacent to the damaged epithelium and focal
inflammatory infiltrates [2,6,7]. CAs have been also detected in
55% of cases in a study of high-grade prostatic intraepithelial
neoplasia in specimens derived from radical prostatectomies [8].
The prostate CA depositions are often of a few millimetres in
diameter, but their bulk weight can in some instances constitute up
to a third of the weight of the prostate gland. The inclusions bodies
coined as CA have been also found in the brain [9], lung [10], ovary
[11] and uterus [10]. Their incidence is commonly associated with
ageing and they may be of a very diversified origin [9–13]. Brain
CAs have been observed much more frequently in patients suffering
from Alzheimer’s disease and other neurodegenerative conditions
rather then in normal ageing [9,14,15]. Indeed, it has been
suggested that in the development of CA in the brain, the initiating
process is most probably degenerative in nature, following the
synthesis of stress proteins [13,16].
Despite the high prevalence of the prostate CAs in later life [17],
this is still a highly disputed area with regard to their nature and
pathological significance in normal ageing and in prostate
pathologies resulting from benign or malignant changes. In
several early studies it was reported that prostatic CAs could
contain amyloid structures [17–19]; however CAs were also
viewed as calcified bodies, prostatic concretion or calculi, resulting
from calcification of precipitated prostatic secretion [20,21] or
arising from simple precipitation of salts normally presented in
prostatic fluid [22]. Localized amyloid deposits, which were not
defined as CA, have been also described in prostate, seminal
vesicles and in the lower urinary tract in some case studies on
human patients by using clinical, radiological, MRI and
immunohistopathological techniques [6,23,24]. The protein con-
tent of some prostate CA inclusions was investigated by
immunohistochemical staining using a panel of antibodies against
the major known in 1990s amyloidogenic proteins [10,17]; b2-
microglobulin was identified, but the antibodies to other proteins,
which were not known as amyloidogenic thus far, have not been
subjected to this examination. Besides this, the application of
immunostaining as a sole method to detect proteins proved to be
unreliable, especially if potential candidates may be present not in
the native state, but in their amyloid form [25].
In the present work we have characterized CA inclusions
extracted from seven radical prostatectomy specimens from
human patients diagnosed with prostate cancer. By using a range
of modern biochemical and biophysical techniques we have shown
that the pro-inflammatory calcium-binding proteins S100A8 and
S100A9, also known as calgranulin A and calgranulin B,
respectively, play an important role in their formation. The
S100A8 and S100A9 belong to a multigenic and multifunctional
family of about 20 members of calcium-binding S100 proteins
[26,27]. A heterodimer of S100A8/A9 has emerged as an
important pro-inflammatory mediator in acute and chronic
inflammation [28–30]. Increased levels of S100A8 and S100A9
have been detected in various human cancers, being abundantly
expressed in neoplastic cells and also in infiltrating immune cells
[29,31–33]. In particular, the enhanced secretion of S100A8 and
S100A9 was found in human prostate cancer cells [34,35].
Altogether, their expression patterns, potential cytokine-like
functions, up-regulation and regulation via signalling pathways,
including tumor-promoting RAGE receptor, suggest that
S100A8/A9 may play a key role in inflammation-associated
cancers [35,36]. Moreover, emerging evidence revealed a general
role for the S100A9 protein in the phenomenon of dystrophic
calcification, specifically in calcifying matrix vesicles and athero-
sclerotic plaques in the arterial wall [37]. It is interesting to note,
that nine out of ten immunohistochemically analyzed S100
proteins of the S100 family were also found in CA deposits in
normal human brain tissue [9]. The S100A8 and S100A9
molecules are characterized by a conformational variability,
adopting hetero and homo-dimeric, trimeric as well as tetrameric
complexes, that can also contribute to their multiple functionality
[38–41]. Although many functions have been identified and
proposed for S100A8/A9, their roles in various biological
processes still remain to be defined. For the first time we report
that S100A8/A9 proteins readily form amyloid structures both in
vivo and in vitro and they are present in the prostate CA inclusions
in their amyloid form.
Results
Protein identification in CA inclusions by mass-
spectrometry
In order to identify the specific proteins within CA, the samples
were solubilized in ice cold TE buffer and analyzed by liquid
chromatography coupled with electrospray ionization mass-
spectrometry (Table 1). In all the specimens examined the data
reveal the presence of 3 major proteins, S100A8, S100A9 and
human serum albumin. A several auxiliary and bacterial proteins
were also identified (Table 1 and 2), but these proteins varied
substantially from patient to patient and their quantities were too
low to be detected by subsequent gel electrophoresis with silver
staining.
Presence of bacteria in CA inclusions.
The CA samples from 5 patients were further analyzed for the
presence of bacterial DNA by the polymerase chain reaction
(PCR) method [42]. Bacterial 16s rDNA was detected in all
specimens (Figure S1). The PCR products were cloned and 5
clones from each specimen were sequenced. Altogether, 13 distinct
sequences (323–338 bps) were identified, 8 of which shared .98%
homology with Escherichia coli sequences, 3 corresponded to
uncultured bacterial clones and 2 showed ,98% homology to
published sequences. 4 out of 5 Escherichia coli rDNA positive
samples have been shown also to contain bacterial proteins
(Table 2).
Amyloid nature of the major proteinaceous components
of CA
The extracts from the CA samples were subjected to SDS-
PAGE electrophoresis and then to Western blot analysis with
polyclonal antibodies towards S100A8, S100A9 and human serum
albumin (Figure 1A). The S100A9 antibodies recognized 14 kDa
monomeric and 28 kDa dimeric species [38–40], the S100A8
antibodies recognized 10 kDa monomeric S100A8 (Figure 1A) in
3 out of 7 specimens analyzed. Both the S100A8 and S100A9
antibodies recognized a 48 kDa species, suggesting the presence of
hetero-tetramers of S100A8/A9 [38–40]. Human serum albumin
antibodies interacted with a ca. 50 kDa molecular species,
indicating the presence of truncated serum albumin (the molecular
weight of the intact protein is 67 kDa). However, aggregated
species with a high molecular weight, and which remained in the
stacking gels, did not interact with anti-serum albumin antibodies.
They were stained by both S100A8 and S100A9 antibodies,
indicating that these aggregates are composed of both these
proteins (Figure 1A).
The CA samples were also subjected to immunohistochemical
analysis, which revealed that they are stained positively with both
S100A8 and S100A9 antibodies (Figure 1B–1D). In the tissues
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adjacent to CA inclusions we observed positive foci of S100A8 and
S100A9, including the S100A8 and S100A9 positively stained
glandular epithelial cells and tissue macrophages, which infiltrate
inflamed glands (Figure 1B and 1C). The co-immunostaining of
CA inclusions with both antibodies towards S100A8 and S100A9
proteins is shown in Figure 1D with higher magnification. By
contrast, only weak staining with serum albumin antibodies was
observed at the edges of the CA inclusions and in the surrounding
tissues (Figure 1E), indicating that serum albumin, detected by
mass-spectrometry and Western blot analysis, came from the
surrounding tissues, and not from the CA bodies. All CA
specimens were also stained with anti-amyloid fibril antibodies
[43] (Figure 1F and 1G) and with Congo red dye, used as a marker
for the presence of the amyloid form of proteins (Figure S2). These
results demonstrate that the amyloid material constitutes a
significant mass of the CA specimens.
Structural characterisation of S100A8/A9 amyloid
formation
Atomic force microscopy (AFM) and transmission electron
(TEM) microscopy were used to examine the ex vivo CA extracts,
and they revealed the presence of a variety of highly heteroge-
neous aggregates (Figure 2). These aggregates include spherical
species of ca. 2–3 nm in height (Figure 2A), some of them
arranged into chain-like sequences, which were closely similar to
the oligomeric precursors of amyloid fibrils described for
numerous peptides and proteins [44–46]. Extensive networks of
fibrillar species of 4–8 nm in height and several microns in length
were observed (Figure 2B and 2O), characteristic of mature
amyloid fibrils. Assemblies of straight and rigid fibrils a few
hundred nanometres in length (Figure 2C) were present in all CA
specimens, as well as there were larger scale super-molecular
assemblies, reaching a few microns in length and up to ca. 500 nm
in thickness (Figure 2D).
In order to examine further the amyloidogenic properties of the
S100A8/A9 proteins we set out to produce their amyloid forms in
vitro. The S100A8/A9 complexes, extracted from granulocytes and
produced recombinantly from Escherichia coli, were each incubated
under the native conditions of pH 7.4 and 37uC with agitation and
at pH 2.0 and 57uC without agitation. The aliquots were collected
regularly for further examination during the period of 2 months;
the sub-millimolar concentrations of metal ions were present in the
samples after the purification procedure [40,47]. Under both
conditions the proteins were found to assemble into heterogeneous
fibrillar species. At pH 7.4, species resembling ex vivo oligomers
and short protofilaments were observed after 2 weeks of
incubation (Figure 2E). Upon further incubation for up to 8
weeks, thick bundles of fibrils with heights of 15–20 nm and a few
microns in length constituted the major population of fibrillar
aggregates (Figure 2F, 2G and 2P).
Table 1. Proteins identified in CA samples from the selected group of patients by liquid chromatography-electrospray ionization
mass spectrometry.
Protein
Accession
number
{Protein
size (kDa)
Number of identified unique peptides ({sequence coverage %) in following
patients (P).
P1 P2 P3 P4 P5 P6 P7
S100A8 IPI00007047 10 2 (24) 1 (11) 1 (11) 2 (24) 2 (24) 3 (31) 3 (31)
S100A9 IPI00027462 13 3 (36) 2 (25) 1 (13) 1 (13) 1 (13) 4 (31) 3 (26)
Human serum albumin IPI00745872 67 10 (24) 6 (14) 24 (60) 16 (38) 13 (31) # 5 (10)
a-1-acid glycoprotein 1 IPI00022429 21 # 1 (8) 2 (13) 2 (24) 1 (8) # #
Zinc-a-2-glycoprotein IPI00166729 32 # # 3 (16) 5 (21) 3 (12) # #
Hemoglobin subunit a IPI00410714 15 2 (14) # 1 (11) # # 1 (11) #
Hemoglobin subunit b IPI00654755 16 1 (9) # # # # # #
Cathepsin G IPI00028064 27 2 (9) # # # # 3 (11) #
Neutrophil defensin 1 IPI00005721 8 1 (12) # # # # # #
Myeloperoxidase IPI00007244 79 1 (2) # # # # 12 (10) #
Prostate-specific antigen IPI00010858 27 # # # # 1 (5) # #
Haptoglobin IPI00431645 31 # # 5 (25) # # # #
{Calculated after removing signal peptide from their precursor sequence. # No significant identification.
doi:10.1371/journal.pone.0005562.t001
Table 2. Escherichia coli (E. coli) proteins identified in CA samples by liquid chromatography-electrospray ionization mass
spectrometry.
Protein Accession number Organism Protein size (kDa)
Co-chaperonin GroES NP_290775 E. coli 10
Heat shock protein GrpE NP_289166 E. coli 22
ATP-dependent protease regulatory subunit CAA40846 E. coli 66
A single peptide from each protein was identified.
doi:10.1371/journal.pone.0005562.t002
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Figure 1. Immunoassays of CA proteinaceous components. (A) Western blots of CA extracts from three representative specimens with
S100A9, S100A8 and human serum albumin antibodies; the staining of aggregates in stacking gel with corresponding antibodies is shown in the right
column. (B and C) Immunostaining of CA and surrounding tissues with S100A8 and S100A9 antibodies, respectively, shown in brown; the positive
S100A8/A9-staining of CA (1), macrophages in stroma (2), macrophages in epithelium tissues (3) and the focal epithelial staining (4) are indicated by
numbers and arrows. (D) Co-immunostaining of CA inclusions with anti-S100A8 (shown in purple) and anti-S100A9 antibodies (shown in brown). (E)
Lack of CA immunostaining by human serum albumin antibodies (CA body does not display purple colour). (F and G) Immunostaining of the prostate
CA inclusions by antibodies towards amyloid fibrils shown in purple with low and high magnification. The magnification is indicated in left lower
corner of each image.
doi:10.1371/journal.pone.0005562.g001
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In the S100A8/A9 samples incubated at pH 2.0 without
agitation the spherical species and protofilaments also emerged
in 2 weeks (Figure 2H), and after 4 weeks the flexible fibrils with
height of ca. 4–5 nm and microns in length (Figure 2I and 2Q)
were observed together with straight and rigid fibrillar structures a
few hundred nanometres in length (Figure 2K), which resembled
the ex vivo species shown in Figure 2C. Large fibrillar bundles,
reaching ca. 80 nm in diameter (Figure 2J) and resembling the
superstructures shown in Figure 2D, were also regularly found in
specimens incubated for 4–6 weeks.
As ex vivo CA deposits were found to be calcified and to contain
zinc salts, we examined the effect of these ions on amyloid
formation by S100A8/A9. The S100A8/A9 amyloid protofila-
ments of ca. 2 nm height were assembled in the presence of ZnCl2
and in a suspension of Ca3(PO4)2 (Figure 2L and 2M), but not
when EDTA was added in solution even during 2 weeks of
incubation (Figure 2N). These species converted into the fibrillar
assemblies described above upon prolonged incubation, and again
no filamentous structures developed in the presence of EDTA.
Aggregation propensity profiles of S100A8/A9
The identification of the regions of peptide and protein
sequences, that are likely to be most important in promoting
amyloid formation, enables us to predict the behaviour of these
two proteins under given conditions. Intrinsic aggregation
propensity profiles [48,49] of monomeric S100A8 and S100A9
at pH 7.0 and pH 2.0, the conditions which we have used for in
vitro amyloid formation, and in their natively folded S100A8/A9
oligomeric complex were calculated (Figure 3). The overall
aggregation scores for S100A8 are 0.76 at pH 7.0 and 0.77 at
pH 2.0 and for S100A9, 1.04 and 0.65, respectively; the
aggregation score of S100A9 in particular is similar to the
aggregation scores of Ab(1–40) and Ab(1–42) peptides at pH 7.0,
which are equal to 0.97 and 0.94, respectively [48]. In the
S100A8/A9 oligomeric complex (references for the structures: pdb
1xk4 for S100A8 and pdb 1irj for S100A9) the aggregation profiles
(Figure 3) and the scores of 0.18 and 0.32 for S100A8 and
S100A9, respectively, are significantly reduced, indicating that
most of the aggregation-prone sequences are involved in the
oligomeric interactions. In both proteins the calcium-binding sites
with low affinity (amino acid residues 20–33 for S100A8 and 23–
36 for S100A9) and high affinity (amino acid residues 59–70 for
S100A8 and 67–78 for S100A9) are located in close proximity to
the segments that are highly aggregation-prone. As S100A8 and
S100A9 at neutral pH undergo a calcium-dependent oligomeri-
zation rather than amyloid formation [39] and as the intermolec-
ular interactions responsible for native state oligomerization and
aggregation can overlap, calcium-binding is likely to generate
conformational changes that, in addition to promoting native state
oligomerization, increase the aggregation process as demonstrated
above. Hence, we surmise that the evolution of a calcium-
dependent oligomerization required to generate the native
functional state, has come at the cost of a higher calcium-
dependent aggregation propensity.
Analysis of the mineral phases of CA
In order to determine the mineral components of CA inclusions,
the powdered CA samples were subjected to x-ray photoelectron
spectroscopy (XPS) analysis. A typical XPS spectrum of CA
(Figure 4A) reveals the presence of C, N, O, P, Ca, K, Zn and Mg
atoms. The binding energies derived from the Ca 2p3/2 (347.4 eV)
and P 2p3/2 (133.2 eV) lines and the Ca/P atomic ratio
(1.3:1.060.2) indicate the presence of calcium phosphate phases
as a major inorganic component of CAs. The existence of
hydroxylapatite (Ca5(PO4)3OH) (Figure 5A) and whitlockite
(Ca2(PO4)3) (Figure 5B) crystalline phases in various CA samples
was also confirmed by x-ray powder diffraction measurement. The
atomic concentrations of Zn (ca. 0.3 atomic %) and Mg (1.5–2.0
atomic %) indicate that these ions are incorporated into the
calcium phosphate phases to form crystalline compounds, in which
up to 20% of Ca cations are substituted by Zn or Mg. The atomic
concentrations and binding energies corresponding to the
photoelectron lines of N 1 s (NH, 400.0 eV, atomic concentration
5–6%), C 1 s (C2(C,H), 285.0 eV, atomic concentration ca.
13.5%; C2(O,N), 286.4 eV, atomic concentration ca. 5.7%;
COOH, 288.1 eV, atomic concentration ca. 5.6%) and O 1 s
(532.5 eV, atomic concentration ca. 6.9%) indicate that the
remaining component of CA is proteinaceous in nature (NIST
Standard Reference Database 20). A sample of CA was also
probed at 350uC in an ashing furnace, which resulted in a 32%
weight loss; this observation indicates that 30–40% of CA is
organic in nature. XPS spectra recorded for the CA sample from
different patients showed that the variation in the weight of
mineral and organic compounds was within 10–20% and the
variations in Zn content were within 0.1–0.5 atomic %. Consistent
with the XPS analysis, the Fourier transform infrared spectrum of
CA powder shows characteristic amide I–III bands of 1700–
1359 cm21, corresponding to peptide bonds in the proteinaceous
phase, and the broad bands at 1100–900 cm21 and 650–
500 cm21, which can be attributed to the vibration mode of the
phosphate group in calcium phosphate (Figure 4B).
Discussion
The results described in this study demonstrate that the prostate
CA inclusions are primarily composed of calcified amyloid forms
of the pro-inflammatory S100A8/A9 proteins. As prostatic fluid is
very rich in protein content [50,51], it is not unexpected that small
quantities of a range of other proteins were also found in the CA
inclusions, presumably being trapped in the aggregating and
growing deposits (Table 1 and 2). We have not detected b2-
microglobulin reported previously in CA deposits by immunohis-
tochemical analysis [17], even through we were able to detect
small traces of bacterial proteins due to the high sensitivity of the
liquid chromatography-electrospray ionization mass spectrometry
technique, utilized in this study. We have investigated here the CA
inclusions from the Scandinavian population; although probability
cannot be excluded that prostate CA deposits can be diversified in
their origin, depending on ethnic and geographical factors as well
as their clinical history. Extended epidemiological studies on the
Figure 2. AFM and TEM imaging of ex vivo and in vitro S100A8/A9 amyloid structures. (A) AFM images of ex vivo amyloid oligomers, chain-
like sequences are indicated by blue arrow; (B) ex vivo amyloid fibrillar network; (C,D) TEM images of ex vivo amyloid superstructures; (E) AFM images
of S100A8/A9 oligomeric assemblies produced at pH 7.4, 37uC with agitation after 2 week of incubation, (F,G) fibrillar bundles produced at pH 7.4,
37uC with agitation after 8 weeks; (H–K) heterogeneous types of S100A8/A9 amyloids produced at pH 2.0 and 57uC after 4 weeks of incubation with
residual content of Ca and Zn. S100A8/A9 amyloids produced at pH 2.0 and 57uC after 2 weeks of incubation in the presence of (L) 1 mg/ml
powdered Ca3(PO4)2 and (M) 10 mM ZnCl2; (N) aggregates observed in the presence of 50 mM EDTA. AFM cross-section analysis of amyloid
structures indicated by red lines in corresponding images (O from B; P from F and Q from I). Scale bars are shown in white and equal to 250 nm in all
AFM images.
doi:10.1371/journal.pone.0005562.g002
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male populations from different geographical and climate zones
would be of significance in addressing this issue as well as in
revealing the causative factors affecting the geographic pattern of
prostate cancer incidence discussed above [3,4].
In inflamed tissues adjacent to the CA inclusions we have
commonly observed S100A8 and S100A9 positive focal epithelial
cells and macrophages (Figure 1B and 1C). These activated cells
may contribute to the rise in the concentrations of S100A8 and
S100A9 at the sites of inflammation. As amyloid formation is a
concentration-dependent process, the increasing concentration of
aggregation-prone proteins in the sites of inflammation would
favour their amyloid assembly and deposition in the CA (Figure 6).
The finding of Escherichia coli DNA (Figure S1) and Escherichia coli
proteins (Table 2), in the CA deposits makes it possible to
hypothesize that CA formation may be associated with bacterial
infection, taking place in the prostate during the prolonged course
of their initiation and growth. Indeed, we and others have detected
Escherichia coli in the prostate tissues [52–54] Therefore the CA,
entrapping biological molecules such as Escherichia coli DNA and
proteins, may represent a snapshot of the prostate history with
regards to bacterial infection affecting the prostate gland during
their formation. As a CA grows and the inflammatory process
spreads, neighbouring acini are obstructed and the cycle can
continue.
Figure 3. Intrinsic aggregation propensity profiles. (A) S100A8 and (B) S100A9 aggregation propensity profiles denoted at pH 7.0 by red, at
pH 2.0 – by turquoise and in the natively folded S100A8/A9 complex – by blue lines, respectively. Calcium-binding sites are indicated by green, a-
helices – by black and b-strands – by blue bars, respectively.
doi:10.1371/journal.pone.0005562.g003
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Other amyloid diseases are known to be associated with chronic
inflammation, including Alzheimer’s and Parkinson’s diseases,
although it is far from clear, which role multifunctional
inflammatory mediators play in different pathophysiological
situations [55–59]. Growing evidence indicates that an abnormal
deposition of fibrillar Ab peptide in the brain can be accompanied
by inflammatory responses and increasing production of pro-
inflammatory cytokines in microglia. Amyloid formation by the
pro-inflammatory S100A8/A9 proteins, their deposition in the
ageing prostate and their association with local inflammatory
reactions, all emphasise the role of persistent inflammation in the
prostate pathogenesis. Growing CA deposits may induce further
degradation of epithelial tissue in the prostate gland, exacerbating
inflammation and, therefore, potentially contributing to neoplastic
transformation [2,5,7]. Studies on a larger number of prostate
samples, including both neoplastic and non-cancerous prostate,
would further clarify this issue and should generate a link between
the pathological cascade including infection, inflammatory
response and amyloid deposition with benign and malignant
transformations in the prostate gland.
The identification of bacterial DNA and proteins in CA,
including the highly amyloidogenic co-chaperonin GroES [60],
can be related not only to the fact that bacterial infection is a
contributory factor to inflammation, but suggests the potential role
of bacterial infection in amyloid depositions (Figure 6). Currently,
the link between amyloid formation and bacterial and viral
infections receives growing attention [61–63]. In particular, it has
been shown that semen-derived amyloid fibrils of the fragments of
prostatic acidic phosphatase drastically enhance HIV infection in
humans [64]. It would be important to examine whether the
amyloid structures of S100A8/A9 proteins in prostate may act as a
seed, promoting the amyloid formation of prostatic acidic
phosphatase fragments in prostatic fluid. It is not excluded that
the amyloid structures of bacterial origin such as amyloidogenic
chaperonin GroES may also contribute to amyloid seeding of
S100A8/A9 proteins themselves. Indeed, it has been demonstrat-
ed that curli from Escherichia coli and Sup35 from Saccharomyces
cerevisiae can exert amyloid-accelerating properties in the murine
serum AA amyloidosis [65]. The biochemical link between viral
infection and the development of the Alzheimer’s disease
pathological features has also been examined [62,63] and the
authors suggested that herpes simplex virus type 1 can directly
contribute to the development of senile plaques. While the amyloid
fibrils in bacteria, fungi insects and in de novo design were found to
fulfil useful functions [66,67], amyloidogenesis in general still
requires tight regulation to avoid amyloid toxicity. In most cases
amyloid fibrils are detrimental in the host, leading to pathologies.
Due to their high potency in seeding and cross-seeding, the
misfolding of proteins into an amyloid state can be a general origin
of infectivity, which was highlighted in the phenomenon of
amyloid formation and propagation by prion proteins [68].
The hetero-oligomeric complexes of S100A8/A9 are charac-
terised by significant stability and protease resistance comparable
to these of prions [41]. In the protease rich environment of
prostate gland, and especially at sites of inflammation, proteases
are present at even higher levels than in other tissues. Protease
resistance of the S100A8/A9 proteins could favour their
accumulation and conversion into amyloid structures in prostate
tissue. The bundles of amyloid fibrils of S100A8/A9 proteins, that
are formed both in vivo and in vitro (Figure 2), are amongst the
largest super-molecular species reported for amyloid assemblies
[69]. The lateral association or thickening of the fibrils is likely to
be a contributory factor to their stability in the prostate gland.
Indeed, it has been suggested that the various functions of the
S100A8/A9 hetero and homo-oligomers may be regulated by
their differential protease sensitivity [41]. If so, the amyloid
structures formed by the S100A8/A9 will be at the extreme end of
the scale of resistance to proteolysis.
A recently reported function of S100A9 is associated with the
promoting calcification [37], suggesting that this protein may also
play a role in dystrophic calcification of CA deposits. The mineral
content of CA was rather uniform in all the patients we studied
(Figure 4A), suggesting that calcification is a regulated process and
therefore could be influenced by the activities of S100A8/A9. In
our in vitro studies we have shown that the formation of the
amyloid structures of the S100A8/A9 proteins is promoted by the
presence of calcium and zinc. The experimental observations were
also supported by computational analysis of aggregation propen-
sity profiles, demonstrating that the aggregation-prone regions are
located in close proximity to the calcium- binding sites in both
proteins. In the case of the S100A8/A9 proteins calcium-binding
affects the competitive processes of protein folding and aggrega-
Figure 4. Chemical content of CA inclusions. (A) XPS survey and (B) FTIR spectra of powdered prostate CA material.
doi:10.1371/journal.pone.0005562.g004
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Figure 5. X-ray powder diffraction patterns of CA inclusions. (A) Hydroxylapatite 2 (Ca5(PO4)3OH) and (B) whitlockite 2 (Ca2(PO4)3)
crystalline phases of CA.
doi:10.1371/journal.pone.0005562.g005
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tion, while proteins themselves influence the process of calcifica-
tion, which together may produce a synergistic effect, leading to
the further enlargement of CA deposits (Figure 6).
Thus, the direct involvement of pro-inflammatory S100A8/A9
proteins in CA biogenesis, which we reported here for the first
time, emphasizes their role in the age-dependent prostate
remodelling and accompanied ailments (Figure 6). The discovery
of the link between amyloid formation and prostate pathogenesis
supports the paradigm that the generic ability of polypeptides to
assembly into this stable form as an alternative to the native state
[70,71] is likely to result in its involvement in an increasing
number of age-related diseases. The disorders as apparently
unrelated as Alzheimer’s and Parkinson’s diseases and prostate
pathologies can all be linked by the common phenomenon of
amyloid formation. In all these diversified diseases inflammation
can be an important causative factor in amyloid depositions. This
Figure 6. Inflammation-dependent pathways of the prostate CA formation. Infection, inflammation and amyloid self-assembly of S100A8/
A9 proteins in the presence of calcium or/and zinc are important factors leading to CA depositions in the prostate gland.
doi:10.1371/journal.pone.0005562.g006
Amyloidosis in Prostate
PLoS ONE | www.plosone.org 10 May 2009 | Volume 4 | Issue 5 | e5562
conclusion gives further support to the strategies aiming at
averting inflammation in order to treat and possibly prevent
amyloid formation and also potential neoplastic developments in
prostate.
Materials and Methods
CA specimens
CA specimens were dissected from the prostate tissue from
seven patients undergoing radical prostatectomy due to prostate
cancer. All patients gave their written informed consent and the
collection of human tissues was approved by the Umea˚ research
ethics board. The specimens were washed in sterile PBS and
stored at 280uC.
Protein samples
Human S100A8/A9 proteins were isolated from granulocytes as
a heterodimer and stored in 20 mM Tris, 1 mM DTT, pH 7.2
[47]. Recombinant human S100A8 and S100A9 were expressed in
Escherichia coli, their complex was produced as described previously
[40] and they were kept in 20 mM Hepes, 140 mM NaCl, pH 7.4.
The amyloid was produced by incubation of both purified from
granulocytes S100A8/A9 complexes at 3.5 mg /ml and recom-
binant S100A8/A9 complexes at 2.3 mg/ml in 50 mM HCl,
pH 2.0, 57uC without agitation and in the original buffers at
pH 7.2 (pH 7.4), 37uC with agitation. All reagents were purchased
from Sigma, unless stated otherwise.
CA extractions
CA specimens were incubated in undiluted methanol at 4uC
overnight, washed 3 times and ground in a glass homogenizer,
adding ice cold TE buffer (20 mM Tris-HCl, 10 mM EDTA,
pH 7.5) [72]. The homogenized material was centrifuged at
15000 g in a mini-centrifuge (Eppendorf). The pellet was re-
suspended 3–4 times in TE buffer, homogenized through a
21gauge needle of 2 ml syringe and centrifuged again. TE buffer
was sterilized and only sterile needles and syringes were used
during the extraction procedures. All supernatants containing
proteins were collected and stored at 220uC.
CA extract tryptic digestion and peptide analysis by
liquid chromatography-electrospray ionization mass
spectrometry
CA extracts in 0.2 M NH4HCO3, 15 mM DTT were incubated
at 95uC for 15 min, cooled to room temperature, mixed with 8 M
urea and incubated for 1 h. Subsequently, the alkylation reaction
was carried out at 37uC for 30 min in darkness in the presence of
80 mM iodoacetamide. Urea concentration was reduced to 0.8 M
by diluting with 0.2 M NH4HCO3. Trypsin was added at 1:40
enzyme-to-substrate ratio and tryptic digestion was carried out
overnight at 37uC. It was stopped by adding formic acid to the
final concentration of 0.5%. The resulting peptides were
lyophilized and re-suspended in 1% TFA. Then they were
desalted by using a Poros 50 reverse-phase R2 material
(PerSeptive Biosystems) prepared in a GELoader tip (Eppendorf)
as described previously [73]. The peptides were eluted from the
R2 micro-column by using 80% acetonitrile with 0.1% TFA,
lyophilized and re-suspended in 0.1% formic acid.
Subsequently, the tryptic peptides were subjected to a reversed-
phase ultra-performance nano ACQUITY UPLCTM system
(Waters). Each peptide sample was concentrated in a C18 trap
column with symmetry of 180 mm620 mm, 5 mm and washed
with 5% acetonitrile and 0.1% formic acid at 15 ml/min speed for
1 min. The samples eluted from the trap column were subjected to
a C18 analytical column (75 mm6100 mm, 1.7 mm) at 600 nl/
min flow speed, using 0.1% formic acid as a solvent A and 0.1%
formic acid in acetonitrile as a solvent B in a gradient. The
following gradients were applied: linear from 0 to 40% B in
25 min, linear from 40 to 80% B in 1 min, isocratic at 80% B in
1 min, linear from 80 to 5% B in 1 min and isocratic at 5% B for
7 min.
The eluting analytes were sprayed into a Q-Tof UltimaTM mass
spectrometer (Waters) with the capillary voltage set to 2.6 kV and
cone voltage to 40 V. The instrument was calibrated using MS/
MS fragments of GluFib peptide (Sigma Aldrich) and the samples
offset calibration was performed as described previously [74]. The
acquisition of MS/MS spectra was performed with an automated
data-directed switching between the MS and MS/MS modes
using the instrument software (MassLynx V4.0 SP4). The three
most abundant signals of a survey scan (400–1300 m/z range,
0.87 s scan time and 0.13 s inter-delay) were selected by charge
state, and collision energy was applied accordingly for sequential
MS/MS fragmentation scanning (50–2000 m/z range, 0.9 s scan
time, 0.1 s inter-delay). ProteinLynx Global Server software
(V2.2.5) was used to convert raw data to peak lists for database
searching.
The negative control measurements with the ice cold TE buffer
and 0.2 M NH4HCO3, 15 mM DTT buffer used for dissolving
CA material were performed. These solutions were subjected to
the same procedures as the CA samples to exclude the general
background level of contaminations.
Protein identification by database analysis
Proteins were identified by a local version of Mascot search
program V2.1.04 and Mascot Daemon application V2.1.6 (Matrix
Science Limited, http://www.matrixscience.com), using human
sequence library in the International Protein Index (IPI) database
(IPI_human_20080409, 72,340 sequences). The following settings
were used for the database search: trypsin-specific digestion with
one missed cleavage allowed, carbamidomethylated cysteine set as
fixed modification, oxidized methionine and deamidation in
variable mode, peptide tolerance of 60 ppm and fragment
tolerance of 0.1 Da. Peptides with Mascot ion scores exceeding
the threshold for statistical significance of p,0.05 were selected
and also re-processed manually to validate their significance.
Western blot analysis
Gel electrophoreses were performed under reducing conditions
by using 8–25% Phast gradient gels. Pre-stained molecular weight
‘‘SeeBlue’’ standards (Invitrogen) were included in each experiment.
In Western blots, proteins were electro-transferred to nitrocellulose
membranes by a Phast-system equipment (GE Healthcare). Non-
specific reactivity was blocked by 5% non-fat milk in Tris-buffered
saline, containing 0.05% Tween 20 (TBS-T) at 37uC for 1 h,
washed 365 min with TBS-T and incubated with polyclonal rabbit
anti-human S100A8, S100A9 (Santa Cruz) and serum albumin
(Sigma) antibodies at 4uC overnight. The membranes were washed
365 min with TBS-T and incubated in the presence of horseradish
peroxidase conjugated with anti-rabbit IgGs (GE Healthcare) at
1:5000 dilution in TBS-T containing 5% non-fat milk at 37uC for
1 h. The blots were washed 3615 min with TBS-T and the
immuno-reactive proteins were detected by using the enhanced
chemiluminescence kit (GE Healthcare).
Immunohistochemistry
Archival prostate samples from patients with prostate cancer
were dewaxed in xylene and dehydrated in ethanol series. After
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antigen retrieval in 10 mM Tris, pH 9.0 they were incubated with
rabbit polyclonal anti-human S100A8, S100A9 (Santa Cruz) and
serum albumin antibodies (Sigma). The CA samples were also
stained with anti-amyloid fibril antibodies [43]. The immune
reactivity was detected by an anti-rabbit IgG peroxidase Immpress
reagent kit, followed by a Vector VIP or Vector DAB peroxidase
substrate kits (Vector Laboratories Inc.). Negative controls were
performed by substituting the primary antibodies with PBS or
irrelevant antibody.
16s rDNA PCR and sequencing
CA aseptically removed from fresh prostatectomy samples were
washed in sterile PBS prior to DNA extraction. DNA was purified
by using E.Z.N.A. Blood DNA kit 11 (Omega Bio-TEK). 16s
rDNA PCR and cloning were performed as described previously
[42]. Plasmids were purified by using the QIAprep Spin miniprep
kit (Qiagen) and sequenced by using the T3 primer (MWG
Biotech AG). Database sequence matches to listed organisms were
used to define a phenotype, if the closest match shared .98%
similarity.
Sensitivity of the PCR corresponded to 200 colony forming
units/reaction, which is significantly higher than the general
background level. Stringent anti-contamination precautions to
control PCR contamination were undertaken in the laboratory
environment. The PCR laboratory space has complied or
exceeded standard recommendations for PCR research, including
isolated setup areas with dedicated pipettes, small reagent and
primer aliquots, and use of aerosol-resistant pipette tips. The
buffer solutions involved in the study were subjected to PCR
analysis as negative controls to exclude potential reagent or
laboratory contamination.
Atomic force and electron microscopy
AFM measurements were performed on a PICO PLUS 5500
microscope (Agilent) as described previously [75]. The structural
dimensions were determined by cross-section analysis in height
images. TEM samples were applied to Formvar-coated nickel
grids (400 mesh), stained with 2% uranyl acetate and viewed in a
Philips CEM 100 (FEI) microscope. Fibrillar dimensions were
obtained directly from the micrographs.
Optical microscopy
The CA samples were stained with Congo red as described
previously [76]. The samples were analysed under polarised light
in an Olympus SZX10 stereo microscope (Olympus America Inc.)
equipped with 206 GSWH20X eyepieces under 402fold
magnification.
Protein aggregation propensity profiles
Intrinsic aggregation propensity profiles of S100A8/A9 proteins
were calculated as described previously [48,49] by using the pdb
files of 1xk4 for S100A8 and 1irj for S100A9 from the Protein
Data Bank.
XPS spectrometry
XPS spectra were recorded using a Kratos Axis Ultra DLD
electron spectrometer (Kratos Analytical) equipped with a
monochromated Al Ka x-ray source operating at 150 W, a hybrid
lens system including magnetic lenses and with a charge
neutraliser [77]. The CA samples were instantly frozen and
transferred to the analysis chamber with 2–461027 Pa base-
vacuum, 2150uC. The wide-scan spectra (160 eV pass energy)
and high resolution spectra of all elements (20 eV pass energy)
were acquired. The binding energy scale was referenced to the C
1 s line of aliphatic carbon set at 285.0 eV. The spectra were
processed by using a Kratos software. X-ray powder diffraction
measurements were conducted on a D8 Advance powder
diffractometer (Bruker).
Fourier transform infrared spectroscopy
The infrared spectra of solid samples were collected using a
diffuse reflectance cell (Harrick Scientific) and a IFS-66V/S
spectrometer (Bruker). 300 spectra at a resolution of 4 cm21 were
averaged over 4000–370 cm21 range.
Thermogravimetry
Prior to burning the CA sample was subjected to UV/ozone
radiation for 10 min and then was burned at 350uC in an ashing
furnace (Carbolite) for 4630 min. The gradually decreasing
weight of CA was measured by using AE100 microbalances
(Mettler Toledo) with an accuracy of six digits after each time
interval until the weight remained constant.
Supporting Information
Figure S1 PCR analysis of CA inclusions. Escherichia coli 16s
rDNA detected in five patient specimens are shown in lines (1–5),
negative control - in line (6), wX174 RF DNA marker - in line (7).
Found at: doi:10.1371/journal.pone.0005562.s001 (0.14 MB JPG)
Figure S2 Congo red staining of CA. CA inclusions were stained
with Congo red and observed in polarized microscope with 40-fold
magnification.
Found at: doi:10.1371/journal.pone.0005562.s002 (0.09 MB JPG)
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